1. CEO Message

Sovargen is a biotechnology company founded by the faculty of the Korea Advanced Institute of Science and Technology or KAIST, based on the novel research performance and achievements of Professor Jeong Ho Lee, who is a prominent leader in the field of neuroscience in rare developmental brain disorders. And his research opens up a potential opportunity to unravel the tangles of genomic variation that caused of epilepsy, brain tumor, and Alzheimer's, and others.

Together with Dr. Adrian Krainer, who has contributed to the development of Spinraza, the world's first ASO treatment for the spinal muscular atrophy, or SMA, Professor Lee was awarded the honor of Early-Career Scientist Winner from the 3rd Innovators in Science Award sponsored by The New York Academy of Sciences or NYAS, of the United States in 2020. Moreover, in 2019, Professor Lee was appointed as the head of National Research Leadership in the field of neurological brain disorders based on his domestic and international recognition and commendation.

Sovargen has a robust animal testing lab in tandem with competent R&D scientists and drug development teams that dedicated their passion to deliver safer and more effective medicines for every patient with incurable brain diseases. And we aspire to give life-changing treatments by continue seeking opportunities for open collaboration partnerships with global research institutions and biopharmaceutical companies.

Sovargen cares about the patients, employees, and partners by giving them an equal, fair, and diverse opportunity for a better future and values of life. We are happy to make a promise to you that we will do our best to grow into a world-leading biopharmaceutical company sooner and make the world better.